Expert Interview
Third look: Discussing the upcoming PDUFA for Axsome Therapeutics' AXS-05 (Auvelity) for Alzheimer's Disease Agitation (ADA)
Ticker(s): AXSM, OTSKY, HLBBFInstitution: NYU Langone
- Professor of Neurodegeneration and Alzheimer's Disease at NYU Langone.
- Role includes directing the CURE AD Lab, which is committed to elucidating molecular mechanisms underlying neurodegeneration and enhancing the preclinical pipeline for novel Alzheimer’s therapeutics.
- Lead the Fisher Center Alzheimer's Clinical Trials Program, which is integral in conducting both industry-sponsored and investigator-initiated clinical trials. Our program has been instrumental in the phase III trials of monoclonal antibodies, Leqembi and Kisunla
How many Alzheimer's Disease patients do you manage?
Added By: wilson_adminHow big of an issue is managing ADA in practice?
Added By: wilson_adminDo you think Auvelity is likely to get the sNDA approved?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
